Targeting Glioblastoma Signaling and Metabolism with A Re-Purposed Brain-Penetrant Drug
J. Bi, A. Khan, J. Tang, S. Wu, W. Zhang, R. C. Gimple, T. Koga, A. M. Armando, S. Miki, H. Yang, B. Prager, E. J. Curtis, D. A. Wainwright, F. B. Furnari, J. N. Rich, , P. S. Mischel
This study identifies fluoxetine as a potential therapy for glioblastoma by inhibiting SMPD1 and enhancing temozolomide efficacy, with real-world evidence suggesting improved survival.
bioRxiv · Mar 16, 2021Cancer Biology